Nevertheless, we observed significant differences in the increased soluble levels of MIF in women with BC in comparison with CS in the heterozygous 5,6 carriers [8.95 ng/mL (BC) vs 4.6 ng/mL (CS) P < .01], homozygous 6,6 carriers [11.08 ng/mL (BC) vs 5.7 ng/mL (CS), P < .001)], and homozygous 7,7 carriers [18.8 ng/mL (BC) vs 2.3 ng/mL (CS), P < .001)] (Figure 3B). The gene discussed is MIF; the disease is breast cancer.